iotaMotion Gains FDA Clearance for iotaSOFT Pediatric Use
iotaMotion, Inc., the innovator behind the iotaSOFT® Robotic-Assisted Cochlear Implant Insertion System, has announced significant news regarding the system's capabilities. Recent clearance from the U.S. Food and Drug Administration (FDA) allows the use of iotaSOFT for pediatric patients, specifically those four years and older. This expansion significantly increases access to robotic-assisted cochlear implantation for school-aged children.
Milestone Achievement for Families and Healthcare Providers
Mike Lobinsky, the CEO of iotaMotion, expressed the magnitude of this achievement, stating, "Receiving FDA clearance for expanded pediatric use marks a significant milestone for iotaMotion and for families navigating cochlear implant decisions." This new approval paves the way for families to make well-informed choices regarding cochlear implantation for their children, enhancing the decision-making process.
Understanding the iotaSOFT System
The iotaSOFT Insertion System offers precise and controlled electrode array insertion, crucial for successful cochlear implant surgeries. By standardizing this critical step, iotaSOFT assists surgeons in minimizing variability during surgery, which is a primary concern in preserving sensitive cochlear structures. This reliability is vital in encouraging parents to consider surgical options for their kids.
Cincinnati Children’s Hospital Leads Adoption
Cincinnati Children's Hospital has already adopted the iotaSOFT system, making it the first nationally recognized pediatric center to utilize this advanced technology. The facility joins over 35 leading cochlear implant centers across the country. This integration signifies a commitment to providing the highest standard of care as it embraces cutting-edge innovations to benefit patients.
Expert Opinions on the Advancement
Dr. Daniel Choo, a leading clinician at Cincinnati Children's, commented on this technological advancement in his field, emphasizing, "Robotic-assisted cochlear implantation represents a meaningful advancement in our cochlear implant program." With personal experiences shared within the medical community, it is evident that the iotaSOFT system will significantly enhance patient outcomes.
The Global Implication of Enhanced Cochlear Implantation
According to the World Health Organization, there are over 430 million individuals globally who suffer from disabling hearing loss, yet fewer than 5% of eligible candidates receive cochlear implants. This discrepancy highlights the urgent need for innovative practices in cochlear implantation. The ability for early access to sound is paramount for children, especially for their speech and language development.
A clinical cohort study published in 2025 illustrated the effectiveness of robotic-assisted techniques. The findings revealed that 85% of patients who underwent robotic-assisted insertion maintained their hearing preservation after one year, compared to 71% in manual insertion groups. Such evidence underscores the reliability and efficiency of robotic assistance in the procedure.
The Future of Cochlear Implants
Marlan Hansen, MD, co-founder and chief medical officer at iotaMotion, shared insights about the iotaSOFT system's future, noting its design aims to protect cochlear integrity during surgery. This is critical as new therapies, including gene-based and regenerative solutions, emerge—focusing on children requires careful and controlled implant placements to maximize the benefit.
About iotaMotion
iotaMotion, Inc. is a groundbreaking medical technology company located in St. Paul, Minnesota. It is devoted to improving cochlear implant procedures through advanced robotic solutions. Its flagship device, the iotaSOFT® Insertion System, is pivotal in ensuring the safety and effectiveness of sensitive surgical procedures.
While the iotaSOFT system is currently available in the U.S., it is undergoing clinical investigation in various other global markets, indicating the company’s commitment to expanding its reach and impact worldwide.
Frequently Asked Questions
What is the iotaSOFT System?
The iotaSOFT System is a robotic-assisted device designed to enhance the precision and safety of cochlear implant insertions.
Who can now use the iotaSOFT system following FDA clearance?
The system is now cleared for use in pediatric patients aged four years and older, expanding access to robotic-assisted cochlear implantation.
What is the significance of this FDA clearance?
This clearance allows families and healthcare providers to consider robotic-assisted cochlear implantation for young children, potentially improving their developmental outcomes.
How does iotaSOFT improve surgical outcomes?
iotaSOFT standardizes electrode insertion, which helps reduce variability during surgery—ultimately preserving delicate cochlear structures.
What are the implications for children with hearing loss?
With enhanced access to cochlear implants, children can receive earlier interventions, which is crucial for their speech and language development, benefiting their overall educational progress.
